GenapSys, headquartered in Redwood City, CA, is a venture backed privately-held company that has created, developed and is producing a market disrupting Genomic Testing system. GenapSys's advisory board includes among others, Ron Davis, Director of Stanford Genome Technology Center, George Church, Professor of Genetics at Harvard Medical School, Eric Topol, Director of the Scripps Translational Science Institute, and Mike Snyder, Director of Stanford Center for Genomics and Personalized Medicine. The company's first product, the GENIUS™ 110 System, will enable customers to replace an expensive and time-consuming sample preparation and sequencing bottleneck with a streamlined workflow for Next Generation Sequencing. Its patented GENIUS system integrates advanced fluidics and analytical capabilities to produce sample-to-answer performance for DNA and RNA sequencing, while dramatically reducing capital and operating expenses.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/15/13	$37,000,000	Series B	Decheng Capital IPV Capital Yuri Milner	undisclosed
11/21/19	$90,000,000	Series C	Foresite Capital	undisclosed
05/27/21	$70,000,000	Series D	Farallon Capital Management Soleus Capital	undisclosed